Nature's shield for the aging brain? plant compound tested against vascular cognitive decline

NCT ID NCT06507488

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 21, 2026 · Last updated Aug 21, 2026

Summary

This trial investigates whether daphnetin, a compound from certain plants, can improve cognitive function in people with vascular cognitive impairment—a condition where reduced blood flow to the brain affects memory and thinking, but not yet dementia. Participants aged 50-80 with mild cognitive issues will take either daphnetin or a placebo daily for six months. Researchers will measure changes in cognitive performance using a standard assessment scale, and also track any new vascular events like stroke or heart attack.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Daphnetin capsule (a plant-derived compound also known as 7,8-dihydroxycoumarin)
What this could lead to
If effective, daphnetin could offer a new treatment to slow or improve cognitive decline in people with vascular cognitive impairment, potentially delaying progression to dementia.
What could go wrong
This is a mid-stage trial, and results may not confirm benefit. The compound's effect on cognition is unproven, and potential side effects are not yet fully known.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 206 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2025

Expected to finish

Jul 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

50 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Be 50-80 years of age (both ends included) 2. Have a complaint of cognitive impairment involving memory and/or other cognitive domains that has persisted for at least 3 months 3. Have a cognitive level that is neither normal nor demented according to Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Criteria ( DSM-V criteria), a Montreal Cognitive Assessment (MoCA scale) score \<26 and ≥18, and a Clinical Dementia Rating (CDR) scale score of ≥0.5 in at least one domain and an overall CDR score ≤1 4. Have a cognitive level that is neither normal nor demented according to DSM-V criteria, a MoCA scale score \<26 and ≥18, and a CDR scale score of ≥0.5 in at least one domain and an overall CDR score ≤1 5. Voluntarily participate in this study and sign an informed consent form. Exclusion Criteria: 1. Previously diagnosed dementia; vascular cognitive impairment not associated with a condition other than dementia that may affect cognition 2. Acute stroke event within 6 months 3. Previously diagnosed hereditary or inflammatory small vessel disease 4. Presence of congenital mental retardation and severe neurological or psychiatric disorders 5. Illiteracy or severe visual or hearing impairment, severe aphasia, and other factors that may preclude cooperation with neuropsychological evaluation 6. Associated depression (Hamilton Depression Scale score ≥ 17), or other unrelated serious mental illness (schizophrenia, bipolar disorder, or delirium) 7. Combined severe cardiac, pulmonary, and renal insufficiency (creatinine \> 2.0 mg/dl or 177 μ mol/L), and severe hepatic impairment (aminotransferases more than 3 times normal) 8. Alcoholism, drug addiction, or ongoing use of medications that affect cognitive assessment, such as tranquilizers, sleeping pills, puberty pills, and cholinergics 9. Malignant tumors that have been clearly diagnosed, vital organ failure 10. Those with bleeding tendency after surgery 11. Pregnant and lactating women are prohibited 12. Severe hypertension (Systolic Blood Pressure(SBP)≥160mmHg and/or Diastolic Blood Pressure(DBP)≥110mmHg) is prohibited 13. Previous allergy or intolerance to the ingredients of Reserpine 14. The subject does not have a stable and reliable caregiver or the caregiver is unable to assist the subject in participating in the study 15. Patients who have participated in other interventional clinical studies within the last 3 months or are currently participating in other interventional clinical studies.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cerebrovascular disorders are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Shenyang First People's Hospital

    RECRUITING

    Shenyang, Liaoning, 110041, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.